

寄件人: 魏慶鵬/CCSB
收件人: 王文炳/CCSB, 鍾孟書/CCSB

日期: 2024年07月01日 (星期一) 11:14上午
主旨: 轉寄: [WARNING: MESSAGE ENCRYPTED]USFDA - FMD 145 EIR - Chunghwa Chemical
Synthesis & Biotech Co., Ltd - 3002806677

FYI

----- 轉寄者 魏慶鵬/CCSB 於 2024/07/01 上午 11:14 -----

寄件者: <melinda.fantene@fda.hhs.gov>
收件者: <patrick.wei@ccsb.com.tw>
日期: 2024/06/28 上午 12:11
主旨: [WARNING: MESSAGE ENCRYPTED]USFDA - FMD 145 EIR - Chunghwa Chemical Synthesis
& Biotech Co., Ltd - 3002806677

06/27/2024
Patrick Wei, President
Chunghwa Chemical Synthesis & Biotech Co., Ltd
Shu-Lin District 1 Tung-Hsing Street New Taipei City, Taipei

Dear MPatrick Wei, President:

The U.S. Food and Drug Administration (FDA) conducted an inspection at Chunghwa Chemical Synthesis & Biotech Co., Ltd, FEI 3002806677, located at Shu-Lin District, 1 Tung-Hsing Street, New Taipei City, Taipei, from 04/08/2024 to 04/12/2024. FDA has determined that the inspection classification of this facility is "voluntary action indicated" ("VAI"). Based on this inspection, this facility is considered to be in a minimally acceptable state of compliance with regards to current good manufacturing practice (CGMP).

A VAI inspection classification indicates that, although investigators found and documented objectionable conditions during the inspection, FDA will not take or recommend regulatory or enforcement action because the objectionable conditions do not meet the threshold for action at this time. Despite this facility inspection classification, FDA recommends that you address any observations noted on the Form FDA 483 issued at the conclusion of the inspection or otherwise conveyed to you following the inspection. If not corrected, the same or similar conditions could lead to a future inspection being classified as "official action indicated" ("OAI").

This letter is not intended as an endorsement or certification of the facility. It remains your responsibility to ensure continued

compliance with CGMP.

An inspection classification of VAI for CGMP compliance will not directly negatively impact FDA's assessment of any pending marketing application referencing this facility. Please note, however, that application approval will depend on a product- and application-specific facility assessment conducted by CDER's Office of Pharmaceutical Quality. This letter does not address or reflect FDA's decision making with respect to any potential non-CGMP compliance issues.

FDA has concluded that this inspection is "closed" under 21 CFR 20.64(d)(3), and we are enclosing a copy of the narrative portion of the Establishment Inspection Report (EIR). It may reflect redactions made by FDA in accordance with the Freedom of Information Act (FOIA) and 21 CFR part 20. This, however, does not preclude you from requesting additional information under FOIA.

If you have any questions regarding this letter, you may contact SCSO, Dell Moller via telephone at 614-227-1108 or email at Dell.Moller@FDA.HHS.GOV.

Sincerely,

Melinda A Fantene
PROGRAM SUPPORT SPECIALIST
300 River Place, Suite 5900 Detroit, MI 48207-4291 Telephone:
(313) 393-8100 Fax: (313) 393-8139/8140

(請參閱附件檔 : *EIR CCSB 06 2024_Reviewed.pdf*)



附加檔案

[EIR CCSB 06 2024_Reviewed.pdf](#)